x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

CME/CE

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD"s CME activities. Our topics span cardiology, diabetes, oncology, women"s health and more. And our CME library is continuously growing, every quarter.

science & medicine medicine

All Episodes

00:06:00

So You Think You Want a TKI?

CME/CE ·

2026/03/04

Faculty: Christina Y. Weng, MD, MBA, FASRS Faculty: Katherine E. Talcott, MD This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series further explores TKI mechanisms and their formulation into sustained-release

en

00:05:15

To Implant or to Inject?

CME/CE ·

2026/03/04

Faculty: Katherine E. Talcott, MD Faculty: Roger A. Goldberg, MD, MBA This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series further explores TKI mechanisms and their formulation into sustained-release delivery

en

00:05:45

Who Needs a TKI? Identifying the Right Candidates

CME/CE ·

2026/03/04

Faculty: Roger A. Goldberg, MD, MBA Faculty: Christina Y. Weng, MD, MBA, FASRS This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series further explores TKI mechanisms and their formulation into sustained-release

en

00:05:30

The Struggle Is Real

CME/CE ·

2026/03/04

Faculty: Katherine E. Talcott, MD Faculty: Roger A. Goldberg, MD, MBA This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series further explores TKI mechanisms and their formulation into sustained-release delivery

en

00:05:30

TKI: The New TKO for Retinal Diseases

CME/CE ·

2026/03/04

Faculty: Christina Y. Weng, MD, MBA, FASRS Faculty: Katherine E. Talcott, MD This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizing challenges with durability and adherence. The series further explores TKI mechanisms and their formulation into sustained-release

en

00:15:15

Targeting CKD-aP at the Source: Key Mechanisms and...

CME/CE ·

2026/02/16

Faculty: Steven Fishbane, MD Faculty: Maurizio Gallieni, MD Drs. Steven Fishbane and Maurizio Gallieni discuss chronic kidney disease-associated pruritus (CKD-aP), a prevalent and under-recognized complication of CKD. They review the epidemiology, pathophysiology, and treatment strategies supported by pivotal phase 3 trials and new European S2k guidelines, including the use of difelikefalin, a kappa-opioid receptor agonist. Additional insights from biomarker analyses in the KALM

en

00:15:15

Case-Based Approach: Managing Hyperkalemia in...

CME/CE ·

2026/02/16

Faculty: Ellie Kelepouris, MD, FACP, FAHA Faculty: Nihar Desai, MD Using a real-world patient case, Drs. Ellie Kelepouris and Nihar Desai examine clinical challenges in managing hyperkalemia among patients with chronic kidney disease (CKD) and heart failure (HF). They explore the use of modern potassium binders to sustain guideline-directed medical therapy (GDMT) with renin–angiotensin–aldosterone system (RAAS) inhibitors and break down the differences between patiromer and sodium

en

00:07:30

Do Not Delay: Timing, Triggers, and Identifying the...

CME/CE ·

2026/02/13

Faculty: Prof. Dr. Johann Bauersachs Faculty: Javed Butler, MD Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitalization, despite adherence to quadruple guideline-directed medical therapy (GDMT) and device

en

00:06:30

GDMT Is Working Fine, Why Add More Therapies? The...

CME/CE ·

2026/02/13

Faculty: Javed Butler, MD Faculty: April W. Armstrong, MD, MPH Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitalization, despite adherence to quadruple guideline-directed medical therapy (GDMT) and device

en

00:06:15

Safety, Clinical Integration, and the Emerging Fifth...

CME/CE ·

2026/02/13

Faculty: Prof. Dr. Johann Bauersachs Faculty: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitalization, despite adherence to quadruple guideline-directed

en

00:05:45

Evidence at a Glance: The Totality of Evidence...

CME/CE ·

2026/02/13

Faculty: Prof. Dr. Johann Bauersachs Faculty: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitalization, despite adherence to quadruple guideline-directed

en

00:07:45

When GDMT Isn’t Enough: Understanding Residual Risk...

CME/CE ·

2026/02/13

Faculty: Javed Butler, MD Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findings show that these patients carry significant annual rates of CV death and heart failure (HF) hospitalization, despite adherence to quadruple guideline-directed medical therapy (GDMT) and device support. For cardiologists, the challenge is

en

00:13:45

Targeting B7-H3 in ES-SCLC: Advancing Targeted...

CME/CE ·

2026/02/10

Faculty: Taofeek K. Owonikoko, MD, PhD This online educational activity reviews the scientific rationale for B7-H3 as a therapeutic target in extensive-stage small cell lung cancer (ES-SCLC). Tune in for recent clinical trial data on B7-H3–directed antibody-drug conjugates in ES-SCLC, including key efficacy and safety outcomes in pretreated populations. Learners will gain practical guidance on identifying appropriate candidates for these therapies based on trial eligibility and

en

00:14:45

GDMT Is Working Fine, so Why Add More Therapies for...

CME/CE ·

2026/02/10

Faculty: Prof. Dr. Johann Bauersachs Faculty: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC Contemporary trial data and global registries consistently show that ambulatory patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event still carry residual risk of cardiovascular death and heart failure hospitalizations. These annual rates have been estimated to exceed 10%–20%, despite adherence to quadruple

en

00:15:30

Progress in Breast Cancer Care: Translating SABCS...

CME/CE ·

2026/01/30

Faculty: Charles E. Geyer Jr., MD, FACP Faculty: Komal Jhaveri, MD, FACP This online educational activity equips clinicians with up-to-date, practice-changing insights from SABCS 2025. Experts review pivotal data across early-stage and metastatic breast cancer, including advances in HER2- and TROP2-directed ADCs, and discuss how these findings can meaningfully inform treatment selection. Participants will learn how to apply new evidence to expand therapeutic options, improve

en

00:43:15

From Pixels to Practice: Advancing HCM Care With...

CME/CE ·

2026/01/28

Faculty: Marc Dweck, BSc, MBChB, PhD, FRCP, FRSE Faculty: Tomaz Podlesnikar, MD, PhD Faculty: Jeanette Schulz-Menger, MD This video series focuses on translating multimodality imaging into practical care for patients with hypertrophic cardiomyopathy (HCM). Expert faculty review echocardiography, cardiac magnetic resonance, and emerging imaging strategies to support diagnosis, guide HCM-specific therapies, including the use of cardiac myosin inhibitors, and monitor treatment

en

00:29:45

No Patient with CKD Left Behind! Emerging CKD...

CME/CE ·

2026/01/16

Faculty: Richard E. Pratley, MD Faculty: David Cherney, MD, PhD Faculty: prof. Hiddo Heerspink Join Drs. Richard Pratley, David Cherney, and Hiddo Heerspink in this extended panel discussion, focused on results of the FINE-ONE clinical trial, which evaluated finerenone—a nonsteroidal mineralocorticoid receptor antagonist—in participants with type 1 diabetes and CKD. The dynamic conversation, which includes patient vignettes regarding the potential treatment implications,

en

00:14:00

Practical Perspectives in Myasthenia Gravis #2:...

CME/CE ·

2025/12/31

Faculty: Diana Castro, MD Faculty: Jonathan Strober, MD This discussion between Drs. Diana Castro and Jonathan Strober focuses on the clinical utility of patient stratification and antibody profiling in generalized myasthenia gravis (gMG). The conversation addresses how age of onset, antibody status (acetylcholine receptor, MuSK, LRP4), and comorbidities can influence diagnosis and management plans. The speakers highlight the limitations of current pediatric assessment tools and

en

00:14:45

Practical Perspectives in Myasthenia Gravis #3:...

CME/CE ·

2025/12/31

Faculty: Diana Castro, MD Faculty: Jonathan Strober, MD Drs. Diana Castro and Jonathan Strober discuss treatment strategies for generalized myasthenia gravis (gMG), focusing on pediatric and adolescent care. They review traditional therapies and newer agents, such as FcRn and complement inhibitors, highlighting the role of antibody status and considerations for thymectomy. The conversation also addresses monitoring challenges, including limitations of clinical scales and the

en

00:11:30

Practical Perspectives in Myasthenia Gravis # 1:...

CME/CE ·

2025/12/31

Faculty: Diana Castro, MD Faculty: Jonathan Strober, MD Drs. Jonathan Strober and Diana Castro examine the diagnostic approach to generalized myasthenia gravis (gMG), with a focus on age-related differences in clinical presentation. They describe early signs in pediatric patients—such as ptosis and impaired extraocular movements—and contrast these with the fluctuating fatigue, bulbar involvement, and proximal muscle weakness more commonly seen in adults. The discussion includes

en

339 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事